VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Ovarian Cancer

Feature Video
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Katie Kosko
Survivors teach medical and nursing students around the world about early disease signs and symptoms.
Brielle Urciuoli
Girls Gone Rx sponsors all-female fitness competitions to raise money for Bright Pink, a nonprofit that focuses on prevention and early detection of breast and ovarian cancer.
 
Kristie L. Kahl
Palliative care can be used at all cancer stages, and can drastically improve patients' quality of life.
Kristie L. Kahl
With the number of treatment options consistently increasing, tumor testing is growing more important to personalize care for women with ovarian cancer.
Kristie L. Kahl
An evening of storytelling among women afflicted by ovarian cancer – whether it be their own diagnosis or a loved one’s – helped to empower individuals to find their voice.
Kristie L. Kahl
Hear from our four Ovarian Cancer Heroes about what inspires them in the fight against the disease.
Kelly Irvin
So, what was the first thing I thought about when I vowed to not think about cancer? Cancer, of course.
Brielle Urciuoli
The Food and Drug Administration (FDA) approved a next-generation sequencing (NGS) companion diagnostic assay that can detect BRCA1/2 genetic mutations, as well as the percentage of genomic loss of heterozygosity (LOH) in patients with ovarian cancer.
Kristie L. Kahl
Albeit growing popularity of at-home genetic testing, it is still necessary to seek professional medical opinions from genetic counselors to help discuss results.
Laurel W. Rice, M.D.
Many patients with ovarian cancer have misconceptions about the care they will receive while on a clinical trial, according to Laurel W. Rice, M.D.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable